Current Edition

Systemic Epigenetic Biomarkers for ALS Improve Early Diagnosis, Treatment, and Trials

Amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease is a devastating, rapidly progressive and invariably fatal neurological disease that attacks the nerve cells responsible for controlling voluntary muscles and for which there is no diagnostic or prognostic test. The disease belongs to a group of disorders known as motor neuron diseases (MNDs), characterised by the gradual degeneration and death of motor neurons. ALS is one of the most common neuromuscular diseases worldwide, affecting around 2 in 100,000 people each year. Magdalena Jeznach, BSc MSc, ALS Project Manager at Oxford Biodynamics Ltd, focuses on systemic epigenetic biomarkers for ALS.